Elevation Oncology Stock Today
| ELEV Stock | USD 0.28 0.20 41.29% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Elevation Oncology is selling for under 0.2818 as of the 20th of March 2025; that is 41.29 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.28. Elevation Oncology has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York. The company has 59.22 M outstanding shares of which 8.79 M shares are currently shorted by private and institutional investors with about 6.75 trading days to cover. More on Elevation Oncology
Moving together with Elevation Stock
Moving against Elevation Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Elevation Stock Highlights
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Elevation Oncology (ELEV) is traded on NASDAQ Exchange in USA. It is located in 101 Federal Street, Boston, MA, United States, 02110 and employs 34 people. Elevation Oncology is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 31.14 M. Elevation Oncology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 59.22 M outstanding shares of which 8.79 M shares are currently shorted by private and institutional investors with about 6.75 trading days to cover.
Elevation Oncology currently holds about 122.54 M in cash with (36.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Elevation Oncology Probability Of Bankruptcy
Ownership AllocationElevation Oncology holds a total of 59.22 Million outstanding shares. Over half of Elevation Oncology's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Elevation Ownership Details
Elevation Oncology Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Elevation Oncology market risk premium is the additional return an investor will receive from holding Elevation Oncology long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | 0.3974 | |||
| Treynor Ratio | 0.4598 |
Elevation Stock Against Markets
Elevation Oncology Corporate Management
| Joseph Ferra | Chief Officer | Profile | |
| Valerie MD | Chief Officer | Profile | |
| RPh PharmD | President, Founder | Profile | |
| Ryan Bloomer | Senior Operations | Profile | |
| Biren Shah | Senior Development | Profile | |
| Brian Sullivan | VP Devel | Profile | |
| Candice Masse | Senior Relations | Profile |
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.